SequelSEC

Tevogen Inc. TVGN

Biological Products, (No Diagnostic Substances) · CIK 0001860871 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$26.14M
Fiscal year ended 2025-12-31
Free cash flow
-$12.39M
Fiscal year ended 2025-12-31

Tevogen Inc. (TVGN) reported net income of -$26.28M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Tevogen Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Tevogen Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$26.14M-$53.56M-$8.84MUnavailable
Net income-$26.28M-$13.73M-$60.48M$4.41M
Research & development$11.11M$31.03M$4.40MUnavailable
Weighted-average diluted sharesshares 3.32Mshares 2.93Mshares 24.75MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expense$4.75K$1.75KUnavailableUnavailable
Diluted EPS$-8.08$-3.50$-2.44Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$15.03M$22.53M$4.44M$953.08K
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Tevogen Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$0$0$0$129.19K
Total assets$4.38M$3.46M$5.51M$357.14M
Current assets$1.54M$2.36M$1.72M$274.36K
Total liabilities$12.62M$10.14M$99.93M$15.06M
Current liabilities$7.07M$9.04M$85.48M$350.45K
Total equity incl. NCI-$8.23M-$6.67M-$94.43M-$33.95M
Temporary (mezzanine) equityUnavailableUnavailable$16.68M$356.86M
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.34M$5.20M$3.42MUnavailable

Cash flow

Tevogen Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$12.33M-$12.00M-$8.17M-$215.40K
Capital expenditures$64.44KUnavailable$133.00KUnavailable
Investing cash flow-$64.44KUnavailable-$133.00KUnavailable
Financing cash flow$11.66M$12.23M$3.87MUnavailable
Net change in cash-$730.62K$230.60K-$4.43MUnavailable
Stock-based compensation$16.22M$40.76MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$342.98MUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

Tevogen Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flow-$12.39MUnavailable-$8.30MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio0.22x0.26x0.02x0.78x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TVGN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-12-31

Difference 16681497 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2022-12-31

Difference 19167869 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.